BR112022001627A2 - Composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invenção - Google Patents
Composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invençãoInfo
- Publication number
- BR112022001627A2 BR112022001627A2 BR112022001627A BR112022001627A BR112022001627A2 BR 112022001627 A2 BR112022001627 A2 BR 112022001627A2 BR 112022001627 A BR112022001627 A BR 112022001627A BR 112022001627 A BR112022001627 A BR 112022001627A BR 112022001627 A2 BR112022001627 A2 BR 112022001627A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- cancer
- pharmaceutical compositions
- methods
- mini
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008185 minitablet Substances 0.000 title abstract 2
- 238000004806 packaging method and process Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 3
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invenção. são divulgadas no presente documento composições farmacêuticas e formas de dosagem incluindo n-[5-(3,5-difluorobenzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-2h-piran-4-ilamino)-benzamida que são úteis no tratamento de pacientes que têm câncer. a presente divulgação também fornece métodos para preparar essas composições farmacêuticas e formas de dosagem, e métodos de tratamento de pacientes com câncer usando as composições farmacêuticas e formas de dosagem fornecidas no presente documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19189386 | 2019-07-31 | ||
PCT/EP2020/071332 WO2021018928A1 (en) | 2019-07-31 | 2020-07-29 | New pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001627A2 true BR112022001627A2 (pt) | 2022-04-19 |
Family
ID=67514405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001627A BR112022001627A2 (pt) | 2019-07-31 | 2020-07-29 | Composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invenção |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220218699A1 (pt) |
EP (1) | EP4003309A1 (pt) |
JP (1) | JP2022543552A (pt) |
KR (1) | KR20220038436A (pt) |
CN (1) | CN114206341A (pt) |
AU (1) | AU2020319662B2 (pt) |
BR (1) | BR112022001627A2 (pt) |
CA (1) | CA3144840A1 (pt) |
IL (1) | IL289927A (pt) |
MX (1) | MX2022001159A (pt) |
TW (1) | TW202120089A (pt) |
WO (1) | WO2021018928A1 (pt) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR046544A1 (es) * | 2003-10-15 | 2005-12-14 | Wyeth Corp | Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados |
KR20080039400A (ko) * | 2005-07-07 | 2008-05-07 | 파남 컴퍼니스 인크. | 고수용성 약물의 서방성 약학 조성물 |
JP5506674B2 (ja) | 2007-07-20 | 2014-05-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換インダゾール誘導体 |
RU2602071C2 (ru) * | 2012-05-23 | 2016-11-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
ES2899953T3 (es) | 2016-05-24 | 2022-03-15 | Nerviano Medical Sciences Srl | Nueva forma cristalina de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida |
TW202329972A (zh) * | 2016-08-10 | 2023-08-01 | 瑞士商赫孚孟拉羅股份公司 | 包含Akt蛋白質激酶抑制劑之醫藥組合物 |
JP7203083B2 (ja) * | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
EP3720424B1 (en) * | 2017-12-08 | 2022-09-21 | F. Hoffmann-La Roche AG | Pharmaceutical formulation |
-
2020
- 2020-07-29 AU AU2020319662A patent/AU2020319662B2/en active Active
- 2020-07-29 JP JP2022505413A patent/JP2022543552A/ja active Pending
- 2020-07-29 BR BR112022001627A patent/BR112022001627A2/pt unknown
- 2020-07-29 WO PCT/EP2020/071332 patent/WO2021018928A1/en unknown
- 2020-07-29 CA CA3144840A patent/CA3144840A1/en active Pending
- 2020-07-29 EP EP20746647.5A patent/EP4003309A1/en active Pending
- 2020-07-29 MX MX2022001159A patent/MX2022001159A/es unknown
- 2020-07-29 KR KR1020227005944A patent/KR20220038436A/ko unknown
- 2020-07-29 CN CN202080055731.XA patent/CN114206341A/zh active Pending
- 2020-07-31 TW TW109126003A patent/TW202120089A/zh unknown
-
2022
- 2022-01-17 IL IL289927A patent/IL289927A/en unknown
- 2022-01-21 US US17/580,875 patent/US20220218699A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4003309A1 (en) | 2022-06-01 |
JP2022543552A (ja) | 2022-10-13 |
IL289927A (en) | 2022-03-01 |
CN114206341A (zh) | 2022-03-18 |
WO2021018928A1 (en) | 2021-02-04 |
MX2022001159A (es) | 2022-02-22 |
CA3144840A1 (en) | 2021-02-04 |
TW202120089A (zh) | 2021-06-01 |
AU2020319662A1 (en) | 2022-02-17 |
KR20220038436A (ko) | 2022-03-28 |
AU2020319662B2 (en) | 2024-02-29 |
US20220218699A1 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
BRPI0517032A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
NO20072631L (no) | Kreftbehandlingsmetode | |
BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
JOP20190191A1 (ar) | وحدات شجرية علاجية | |
BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
BRPI0511714A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal | |
PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
BRPI0510679A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos | |
BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |